Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Total 13F shares
-
43,943,299
-
Share change
-
-2,540,583
-
Total reported value
-
$173,133,718
-
Put/Call ratio
-
39%
-
Price per share
-
$3.94
-
Number of holders
-
96
-
Value change
-
-$18,218,100
-
Number of buys
-
41
-
Number of sells
-
54
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2023
As of 30 Sep 2023,
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) was held by
96 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,943,299 shares.
The largest 10 holders included
Skorpios Trust, RTW INVESTMENTS, LP, Redmile Group, LLC, COWEN AND COMPANY, LLC, MORGAN STANLEY, BlackRock Inc., Lynx1 Capital Management LP, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, and Cormorant Asset Management, LP.
This page lists
96
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.